Akeso Inc. has announced a significant regulatory approval for their innovative treatment, cadonilimab. The China National Medical Products Administration (NMPA) has approved the use of cadonilimab as a first-line treatment for advanced, recurrent, or metastatic cervical cancer as of May 2025. This approval marks an important milestone for Akeso, as cadonilimab, a first-in-class PD-1/CTLA-4 bispecific antibody, has shown significant improvements in progression-free survival and overall survival in various patient subgroups. This development highlights the ongoing impact of cadonilimab in transforming the treatment standards for advanced cervical cancer and underscores its potential global health benefits for women.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.